June 23, 2015
La Jolla, CA
Much has happened over the past few months in the area of patent protection in the life sciences area. We are finally seeing implementation (or lack thereof) of the Biologics Price Competition and Innovation Act (BPCIA) provisions, an increased number of IPRs involving pharma and biotech patents, including challenges by hedge funds, and the Federal Circuit’s latest attempt to address joint infringement. Please join Paul Barker, Jonathan Davies, Rob McCauley, and Sanya Sukduang as they address the following topics:
Who Should Attend: General counsel and in-house patent counsel in the life sciences fields with responsibility for/interest in protecting a company’s intellectual property.
MCLE Credit: Finnegan confirms that this activity has been certified for 4.25 hours of California MCLE.
For more information, please contact Finnegan IP Programs
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Conference
Best Practices in Intellectual Property– A Decade of Dedication to IP Excellence
April 8-9, 2024
Tel Aviv
Conference
2nd Annual Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities
March 20, 2024
Boston
Ad Law Buzz Blog
“Banning” a Banned Ingredients Claim: NAD’s Application (and Expansion) of the FTC’s Green Guides
March 18, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.